Calpain-8 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Calpain-8 (CAPN8; UniProt A6NHC0), produced in HEK293 cells. For use in calcium-dependent protease activity assays, inhibitor profiling, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-Calpain8

In stock

SKU
REC-Calpain8
$498.00

Target Overview

Calpain-8 (UniProt A6NHC0; gene CAPN8; EC 3.4.22.53) is a 703-amino-acid calcium-regulated, non-lysosomal cysteine protease of the calpain superfamily. Unlike the ubiquitous calpain-1 and calpain-2 isoforms, Calpain-8 shows a pronounced expression bias toward gastric tissue — specifically the surface mucus (pit) cells of the stomach — where it has been characterised in membrane trafficking pathways. Its documented substrate includes the β-subunit of the coatomer (COPI) complex, implicating it in regulated vesicular coat dynamics within mucus-secreting epithelium. This recombinant is expressed in HEK293 mammalian cells, a system that supports the post-translational folding and calcium-coordination geometry expected of a functional calpain catalytic domain. HEK293-derived material retains the conformational characteristics necessary for calcium-dependent thiol-protease activity, making it suitable for enzymatic activity assays, substrate identification experiments, and small-molecule inhibitor profiling. The full-length sequence spans 703 residues; researchers should confirm the precise expressed construct boundaries in the accompanying Certificate of Analysis. For antibody validation workflows, this recombinant serves as a defined positive-control antigen. Researchers using the matched Triple Point Biologics antibody reagent (SKU: RP-Calpain8) — validated for Western blot against human CAPN8 — can use this recombinant to establish band identity, determine linear dynamic range on Western blot, and confirm immunoprecipitation specificity. Species cross-reactivity of the antibody is validated for human and predicted for mouse and rat, consistent with the conservation of the CAPN8 locus across mammalian genomes.

Background

Calpain-8 belongs to the classical calpain family of intracellular, calcium-dependent cysteine proteases, a group defined by a conserved papain-fold catalytic core and activation by micromolar-to-millimolar calcium concentrations. While calpain-1 (μ-calpain) and calpain-2 (m-calpain) are broadly expressed, CAPN8 expression is largely restricted to the gastric mucosa, where early biochemical studies identified it as a stomach-specific, M-type calpain — also referred to as nCL-2 (new calpain 2) in the older literature. Its localisation to gastric pit cells and its interaction with COPI coat machinery point to a role in regulated membrane trafficking and, by extension, in the secretory dynamics of mucus production. Beyond its gastric-tissue characterisation, CAPN8 has been identified as a research target in multiple oncology contexts. Song et al. (2024, J Proteomics, PMID 38697284) studied Calpain-8 as a potential biomarker in pancreatic cancer, reporting proteomic evidence that CAPN8 expression correlates with tumour progression via epithelial-to-mesenchymal transition (EMT) and activation of the AKT/ERK signalling axis. This work positions CAPN8 as a candidate for further mechanistic dissection in pancreatic cancer cell-line models, where this recombinant can be used to benchmark activity levels or serve as a standard in proteomics workflows. Separately, a multi-modal machine-learning study of lung cancer gene-expression data (Shi et al., 2024, IEEE J Biomed Health Inform, PMID 38032777) included CAPN8 among features informative for tumour subtype classification, reflecting its appearance in transcriptomic datasets. In developmental biology, Carroll et al. (2024, eLife, PMID 39570288) demonstrated a genetic requirement for dact1/2 — regulators of non-canonical Wnt signalling — in controlling calpain-8 activity during convergent extension and craniofacial morphogenesis in zebrafish, providing an in-vivo framework for studying CAPN8 in tissue-remodelling contexts. A germline-variant exome-sequencing study of testicular germ cell tumours (Cuevas-Estrada et al., 2026, NAR Cancer, PMID 42017013) identified CAPN8 among variants warranting further functional characterisation. Collectively, published data position Calpain-8 as a cysteine protease of interest in gastric physiology, digestive-tract oncology research, and developmental cell biology. This recombinant provides researchers with a defined enzymatic source for in-vitro studies across these contexts.

Applications

  • Calcium-dependent cysteine protease activity assay using fluorogenic peptide substrates
  • Small-molecule calpain inhibitor IC50 determination by fluorometric or HPLC-based cleavage assay
  • Coatomer β-subunit (COPI) substrate cleavage characterisation by SDS-PAGE or mass spectrometry
  • Antibody validation positive control for Western blot (paired with Triple Point Biologics RP-Calpain8)
  • Antibody validation positive control for immunohistochemistry (paired with Triple Point Biologics RP-Calpain8)
  • Immunoprecipitation specificity confirmation using matched antibody RP-Calpain8
  • Proteomics standard for quantitative mass spectrometry workflows in pancreatic or gastric cancer cell-line studies
  • Thermal shift / differential scanning fluorimetry for calcium-binding and inhibitor-binding biophysical characterisation

References

  1. Song N et al. Calpain 8 as a potential biomarker regulates the progression of pancreatic cancer via EMT and AKT/ERK pathway. J Proteomics. 2024. doi: 10.1016/j.jprot.2024.105182. PMID: 38697284.
  2. Carroll SH et al. Genetic requirement of dact1/2 to regulate noncanonical Wnt signaling and calpain 8 during embryonic convergent extension and craniofacial morphogenesis. eLife. 2024. doi: 10.7554/eLife.91648. PMID: 39570288.
  3. Shi Y et al. A Novel High-Dimensional Kernel Joint Non-Negative Matrix Factorization With Multimodal Information for Lung Cancer Study. IEEE J Biomed Health Inform. 2024. doi: 10.1109/JBHI.2023.3335950. PMID: 38032777.
  4. Carroll SH et al. Genetic requirement of dact1/2 to regulate noncanonical Wnt signaling and calpain 8 during embryonic convergent extension and craniofacial morphogenesis. bioRxiv. 2024. doi: 10.1101/2023.11.07.566024. PMID: 37986847.
  5. Cuevas-Estrada B et al. Uncovering novel germline variants associated with testicular germ cell tumors by exome sequencing. NAR Cancer. 2026. doi: 10.1093/narcan/zcag007. PMID: 42017013.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Cytoplasm; Ca²⁺-activated

Frequently Asked Questions

What molecular weight band should I expect for recombinant Calpain-8 on SDS-PAGE or Western blot?

Recombinant Calpain-8 (REC-Calpain8) is expressed from the full 703-amino-acid open reading frame (UniProt A6NHC0), giving a predicted molecular weight of approximately 80 kDa. On reducing SDS-PAGE, the predominant band typically resolves between 78–85 kDa, consistent with HEK293-derived glycosylation and any minor post-translational modifications. No significant processing or autoproteolytic cleavage product is expected under standard denaturing conditions. Purity is confirmed at >90% by Coomassie-stained SDS-PAGE prior to release.

Is recombinant Calpain-8 the full-length protein or a catalytic domain fragment?

REC-Calpain8 is expressed as full-length human Calpain-8 (residues 1–703), not a truncated catalytic domain fragment. This distinction matters for calcium-binding geometry: the full-length construct retains the C2-domain-like region (domain III) and the penta-EF-hand domain (domain IV), both of which contribute to calcium-dependent conformational activation. Because HEK293 cells support the folding environment required for these domains, the recombinant is supplied as an active enzyme rather than a denatured or refolded construct.

What is the documented substrate for Calpain-8 and can I use it in a substrate cleavage assay?

The best-characterised substrate of Calpain-8 is the β-subunit of the COPI coatomer complex, implicating it in vesicular coat remodelling in gastric pit cells. For in vitro activity assays, fluorogenic peptide substrates commonly used across the calpain family — such as Suc-LLVY-AMC or Z-Leu-Arg-AMC — serve as surrogate substrates for initial activity verification and small-molecule screening. Cleavage is calcium-dependent; confirm activity with a no-calcium control. For direct substrate identification work, the recombinant's confirmed activity under native-like conditions makes it suitable for proteomic substrate-trapping approaches.

What buffer conditions and calcium concentration should I use for a Calpain-8 activity assay?

The storage buffer for REC-Calpain8 is 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — formulated without added calcium to preserve enzyme stability during storage. For activity assays, dilute into a reaction buffer of 50 mM Tris-HCl pH 7.5, 50–100 mM NaCl, 1–5 mM CaCl₂, and 5–10 mM DTT (to maintain the active-site Cys in reduced form). Calpain-8 shows calcium-dependent activation; titrating CaCl₂ from 0.5–5 mM allows determination of half-maximal activation for your specific assay format. Keep DTT and calcium added fresh immediately before the reaction.

What starting concentration of recombinant Calpain-8 should I use in an enzyme inhibitor IC50 assay?

A practical starting point for IC50 determinations is 50–200 nM REC-Calpain8 in the reaction well, using a fluorogenic peptide substrate at 50–200 µM (well below or near its apparent Km to remain in a linear velocity regime). At this enzyme concentration, signal-to-background ratios with AMC-releasing substrates are typically adequate for 30–60 minute kinetic reads on a standard plate reader. Confirm linearity of product accumulation over time before committing to a full inhibitor titration. Adjust enzyme concentration downward if substrate depletion exceeds 10–15% of total during the read window.

Can I use recombinant Calpain-8 as a positive control for Western blot with the matched anti-Calpain-8 antibody?

Yes — this is one of the primary intended uses of REC-Calpain8 alongside the matched rabbit polyclonal antibody RP-Calpain8 (/anti-calpain-8-rabbit-polyclonal-antibody). Both were developed and validated in the same laboratory, ensuring epitope accessibility to the denatured recombinant on a membrane. Load 5–20 ng of REC-Calpain8 per lane alongside your lysate samples; a clean band at ~80 kDa confirms antibody performance and transfer efficiency. This pairing is particularly useful when working with non-gastric cell lines where endogenous Calpain-8 expression is low or absent.

How much recombinant Calpain-8 should I load per lane as a Western blot positive control?

For chemiluminescent detection with RP-Calpain8 at a 1:1,000–1:2,000 dilution, 5–15 ng of REC-Calpain8 per lane is sufficient to produce a well-resolved band at approximately 80 kDa without overwhelming adjacent lysate lanes. If using fluorescent secondary antibodies or a lower-sensitivity detection system, scale to 20–50 ng. Run the recombinant in a dedicated lane at the gel edge so it serves as both a size reference and a signal-strength benchmark. Avoid loading more than 50 ng, which can produce trailing artefacts that obscure migration relative to marker.

How should I handle, dilute, and store recombinant Calpain-8 to maintain activity over time?

REC-Calpain8 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol in single-use aliquots. Store at -20°C; avoid repeated freeze-thaw cycles, which progressively reduce cysteine-protease activity. For working dilutions, use the storage buffer itself or a compatible assay buffer — avoid diluting into pure water, which disrupts ionic strength and risks precipitation. Working solutions prepared on ice remain active for 4–6 hours. For experiments requiring dilutions below ~10 nM, add 0.1% BSA (protease-free) to the diluent to reduce adsorptive losses to tube surfaces.

Validation imagery coming soon

Western blot validation figures for REC-Calpain8 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →